Age: 12.0
Sex: F
Vaccine: HPV4
Symptoms: Joint dislocation, Loss of personal independence in daily activities, Pain, Postural orthostatic tachycardia syndrome, Pyrexia
Clinical narrative: POTS/ fainting/sleeplessness/n inability to focus, stomach aches / autonomic neurological disease; Autoimmune Disease/ dysautonomia/loss of appetite; body aches and pain, dislocated joints, chronic pain; Chronic Fatigue Syndrome; She also had a substantial fear of suffering additional and ongoing harms, including but not limited to now being at an increased risk of cancer, and future symptoms and harms; rashes, hives,; rashes, hives,; Autoimmune Disease / heterogenous Autoimmune Disease; On March 10, 2017, Plaintiff had her first episode of vasovagal syncope at school/; Plaintiff received her second dose of Gardasil on March 8, 2017. That evening, she developed a high fever; received her second dose of Gardasil on March 8, 2017.; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a currently adult female patient (pt). On an unknown date, the pt had been diagnosed with common variable immunodeficiency (CVID), well-controlled. There was no information regarding pt's allergies, drug reactions or concomitant medications provided.   On 20-AUG-2014, as 12 years old patient, she received first dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) (dose, route of administration, anatomical location, lot # and expiration date were not specified) , recommended by health care provider which was stated as a safe and effective vaccine for preventing cervical cancer and human papillomavirus (HPV). On 08-MAR-2017, the pt received second dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) (dose, route of administration, anatomical location, lot # and expiration date were not specified).  On 08-MAR-2017, that evening, she developed a high fever. On 10-MAR-2017, the pt had her first episode of vasovagal syncope at school. Subsequent to the pt's quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) inoculation, months progressed, so did pt's injuries. She was seen by multiple physicians and specialists for her complaints which now included, in addition to the above: fainting, body aches and pain, dislocated joints, rashes, hives, an inability to focus, stomach aches, loss of appetite, and sleeplessness. As a result of her post quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, she had to withdraw from school, was unable to work, and was unable to engage in other normal activities that a normal young person would enjoy. The pt was unable to enjoy her childhood or work toward her goal of becoming a physician. Based upon her chronic and severe post quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, on an unknown dates, she had been diagnosed with various medical conditions, including but not limited to, POTS, chronic pain, and chronic fatigue syndrome. Quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) and its ingredients caused pt's autoimmune disease and other related injuries and had resulted in her suffering from severe, debilitating, disabling and painful chronic injuries. The pt contended that her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL)injection caused her to develop serious and debilitating injuries, including but not limited to autonomic, neurological, heterogenous autoimmune disease, POTS, and dysautonomia, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which are alleged herein and all of which were caused by  quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) or otherwise linked to her quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL)-induced autoimmune disorder. As a direct and proximate result of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) the pt had suffered and continued to suffer severe and permanent physical injuries, including, but not limited to, her autoimmune disease and associated symptomatology and has suffered severe and permanent emotional injuries, including pain and suffering. On an unknown dates, she also had a substantial fear of suffering additional and ongoing harms, including but not limited to now being at an increased risk of cancer, and future symptoms and harms associated with her autoimmune disease and other injuries caused by quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL). As a direct and proximate result of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) the pt had suffered economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity and she will continue to incur these losses and expenses in the future.  The outcome of the events was not recovered. The reporter considered the events of postural orthostatic tachycardia syndrome, pyrexia, fear of disease, autoimmune disorder, chronic fatigue syndrome, rash, urticaria, syncope, dysautonomia and joint dislocation to be related to  quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL).  The events of postural orthostatic tachycardia syndrome, pyrexia, fear of disease, autoimmune disorder, chronic fatigue syndrome, rash, urticaria, syncope, dysautonomia and joint dislocation were considered as disabling per reporter.  Upon internal review, the events of vasovagal syncope and autoimmune disorder were determined to be medically significant.